Orforglipron Phase 3 Data: Dr. Michael Weintraub Reviews ATTAIN-1 and ACHIEVE-1 Findings
Автор: Metabolic Care Today
Загружено: 2025-08-21
Просмотров: 225
Описание:
Dr. Michael A. Weintraub, of NYU Langone, reviews phase 3 data from the ATTAIN-1 and ACHIEVE-1 trials of orforglipron, a once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes. He discusses how orforglipron compares with injectable GLP-1 therapies such as semaglutide and tirzepatide, its impact on weight loss and cardiometabolic outcomes, and where it may fit into treatment strategies for patients who prefer oral medications. This conversation also highlights secondary outcomes from the trials, gastrointestinal side effect considerations, and the potential role of orforglipron in expanding access to effective obesity care.
#obesity #glp1 #diabetes #metabolichealth #orforglipron #semaglutide
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
